The process of bringing a new seasonal flu vaccine to market in the United States typically follows a predictable routine. However, this year has presented challenges. Vaccine manufacturers have prepared updated versions of the flu shot, and the FDA has approved these formulations. Normally, the CDC’s Advisory Committee on Immunization Practices (ACIP) would provide recommendations on vaccine administration. However, a federal judge's ruling in March suspended ACIP due to procedural violations in member selection by Health Secretary Robert F. Kennedy Jr. Currently, ACIP is not functional, which affects guidance for the upcoming immunization campaigns.
Experts, including former ACIP members and health officials, have expressed uncertainty regarding the vaccination process without ACIP's guidance. Kennedy has attempted to issue a new ACIP charter, and President Trump signed an executive order to review the vaccination schedule, which may lead to the formation of a new advisory committee. Despite the challenges, experts believe that Americans will likely still receive flu vaccines this fall, although there is less certainty regarding COVID vaccines. Preorders for flu shots have already been placed by manufacturers, and private insurance is expected to cover the vaccines.
The federal Vaccines for Children Program (VFC), which provides vaccines to low-income children, relies on ACIP for recommendations. The necessity of a new vote for flu vaccines under VFC is unclear, but experts are divided on its importance. Delays and confusion in the vaccination process have previously caused issues for providers and patients, as seen last year when guidance on COVID vaccines was issued late, leading to complications in administration and insurance coverage.
